Rosacea is a frequent chronic dermatosis on the central region of the face. It is underdiagnosed and can have a significant impact on the sufferers’ quality of life. It is more often seen in an intermediate age range and is prevalent in women, although it can occur during childhood and severe cases are seen in men. Rosacea has a multiple etiopathogenic basis and different clinical types. The vascular and the inflammatory processes in a deconstructing dermal framework account for the most often found clinical types: erythematous telangiectatic, papulopustular, and phymatous. Ocular rosacea should be properly investigated. The differential diagnosis is made mainly with other facial dermatoses, such as acne, seborrheic dermatitis, atopic dermatitis, periorificial dermatitis, contact dermatitis, dermatomyositis, and lupus erythematosus. Treatment includes refraining from exposition to triggering factors and the use of topical and systemic medication. Topical metronidazole, ivermectin, azelaic acid, and brimonidine, as well as systemic doxycycline, carvedilol, and isotretinoin, are drugs of choice, besides different types of laser.
KeywordsRosacea Phyma Demodex Doxycycline Metronidazole Brimonidine Ivermectin
Antimicrobial peptides found in the mammalian tissue induced by injury or inflammation. They belong to the immune system and work as activators and controllers of immune reactions.
The most common symptom of rosacea, characterized by a transient facial blush or redness. The skin can be lightly rose as if blushed, or it may seem slightly sunburned. Sufferers may refer to itching or pricking during rosacea flares.
System developed by a group of collaborative researchers aiming at the creation of a universal, transparent, and sensitive system to grade the quality of scientific evidence and recommendation power. The GRADE system classifies evidence quality (reliability of the used information) at four levels: high (powerful reliability of the real effect is near the assessed one), moderate (moderate reliability of the assessed effect), low (limited effect reliability), and very low (very limited reliability of the effect assessment). There is a significant uncertainty degree in the findings. Evidence from randomized clinical trials begins with high evidence level; evidence from observational studies begins with low evidence level.
A polypeptide of proteolytic reaction which acts upon protein substrates of varied nature. Kallikrein has a vasodilating direct action, but also an indirect one because of its proteolytic feature.
An important group of zinc-dependent proteolytic enzymes (endopeptidases) that account for the degradation of the extracellular matrix and the basal membranes. The metalloproteinases degrade the matrix macromolecules including interstitial collagen, fibronectin, lamina, and proteoglycan, among others. The expression of many metalloproteinases is increased in the skin of rosacea patients.
Represented by clinical changes resulting from acute or chronic events determined by biochemical and molecular processes caused by ultraviolet radiation exposure.
A rosacea phase determined by sebaceous gland hyperplasia, initially showing erythema, edema, and follicular orifice dilation, followed by the development of fibrous tissue. This process can affect the nose (rhinophyma), the mentum/chin (gnatophyma), the forehead (metophyma), the ears (otophyma), and the eyelids (blepharophyma).
The transcriptome corresponds to the genetic code fraction (DNA) transcribed by the RNA polymerase into the RNA molecules, that is, an organ, tissue, or cell lineage’s total set of transcripts (RNA messengers, ribosomal RNAs, transporter RNAs, and microRNAs).
- 26.Gupta MA, Gupta AK, Chen SJ, Johnson AM. Comorbidity of rosacea and depression: an analysis of the National Ambulatory Medical Care Survey and National Hospital Ambulatory Care Survey – Outpatient Department data collected by the U.S. National Center for Health Statistics from 1995 to 2002. Br J Dermatol. 2005;153(6):1176–81.Google Scholar
- 29.Plewig G, Kligman AM, editors. Acne and rosacea. 3rd ed. Berlin: Springer; 2000. 744 pGoogle Scholar
- 34.Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol. 2015;72(5):749–58. quiz 59–60Google Scholar
- 48.Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51(3):327–41. quiz 42–4Google Scholar
- 60.Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Bradley JS. Rates of antimicrobial resistance among common bacterial pathogens causing respiratory, blood, urine, and skin and soft tissue infections in pediatric patients. Eur J Clin Microbiol Infect Dis. 2004;23(6):445–55.CrossRefPubMedGoogle Scholar
- 63.Yamasaki K, Gallo RL. Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc. 2011;15(1):12–5.Google Scholar
- 72.Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M, et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol. 2012;166(3):633–41.CrossRefPubMedPubMedCentralGoogle Scholar
- 73.Seeliger S, Buddenkotte J, Schmidt-Choudhury A, Rosignoli C, Shpacovitch V, von Arnim U, et al. Pituitary adenylate cyclase activating polypeptide: an important vascular regulator in human skin in vivo. Am J Pathol. 2010;177(5):2563–75.Google Scholar
- 75.Burns T, Breathnach S, Cox N. Griffiths C. Rook’s textbook of dermatology. 2010 ed. UK: Wiley-Blackwell; 2010, p. 43.1–.7.Google Scholar
- 81.Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51(4):499–512. quiz 3–4Google Scholar
- 82.Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part II. Topical and systemic therapies in the treatment of rosacea. J Am Acad Dermatol. 2015;72(5):761–70. quiz 71–2Google Scholar
- 83.Elewski BE, Draelos Z, Dreno B, Jansen T, Layton A, Picardo M. Rosacea – global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol. 2011;25(2):188–200.Google Scholar
- 84.Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield L, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. Cutis. 2013;92(5):234–40.PubMedGoogle Scholar
- 85.van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L. Interventions for rosacea. Cochrane Database Syst Rev. 2015;4:CD003262.Google Scholar
- 89.Yamasaki K, Di Nardo A, Bardan A, Murakami M, Ohtake T, Coda A, Dorschner RA, Bonnart C, Descargues P, Hovnanian A, Morhenn VB, Gallo RL.Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea.Nat Med. 2007 Aug;13(8):975–80.Google Scholar